StratDeck

Two stocks in Healthcare

Oxford Biomedica vs Smith & Nephew: profit, growth, debt and price compared

Smith & Nephew is stronger on 4 of 6 figures: profit margin, debt, price for its expected profit and price trend. Oxford Biomedica is stronger on 2: sales growth and analysts' view.

Figures as of 18 November 2026Yahoo Finance
Explore Oxford Biomedica's storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

Oxford Biomedica and Smith & Nephew side by side
Oxford BiomedicaOXB.LSmith & NephewSN.L
Net margin−23.2%Stronger: 10.1%
Revenue growth, past yearStronger: +9.00%+4.60%
Debt to equity273.1%Stronger: 73.1%
Forward P/ELossStronger: 13.2×
Dividend yield—2.55%
AnalystsStronger: Buy · 8Hold · 17
From its 200-day average−5.2%Stronger: +1.4%

Share price over the past year

  • Oxford Biomedica−13.2%
  • Smith & Nephew−6.8%

20 Nov 202518 Nov 2026

Oxford Biomedica or Smith & Nephew: which is stronger?

  • SN.L

    Which is more profitable?

    Smith & Nephew keeps more of each sale as profit: 10.1% against −23.2%.

  • OXB.L

    Which is growing its sales faster?

    Oxford Biomedica is growing its sales faster: +9.00% over the past year, against +4.60%.

  • SN.L

    Which has borrowed less?

    Smith & Nephew has borrowed less: its debt is 73.1% of what its shareholders own, against 273.1% for Oxford Biomedica.

  • SN.L

    Which costs less for the profit it is expected to make?

    Smith & Nephew is expected to make a profit over the next year, where Oxford Biomedica is expected to make a loss.

  • Which pays more in dividends?

    Smith & Nephew pays 2.55% a year in dividends for what a share costs, where Oxford Biomedica pays none.

  • OXB.L

    Which do analysts rate higher?

    Analysts are warmer on Oxford Biomedica: Buy, against Hold for Smith & Nephew.

  • SN.L

    Which is in the stronger price trend?

    Smith & Nephew's price is in the stronger trend: 1.4% above its 200-day average, against 5.2% below.

What each company does

OXB.LOxford Biomedica

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.

Reports results on 25 March 2027

SN.LSmith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally.

Reports results on 1 March 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every UK healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.